Journal article
Cost-effectiveness of initiating pharmacological treatment in stage one hypertension based on 10-year cardiovascular disease risk: a Markov modeling study
- Abstract:
-
Antihypertensive drug treatment is cost-effective for adults at high risk of developing cardiovascular disease (CVD). However, the cost-effectiveness in people with stage 1 hypertension (140-159 mm Hg systolic blood pressure) at lower CVD risk remains unclear. The objective was to establish the 10-year CVD risk threshold where initiating antihypertensive drug treatment for primary prevention in adults, with stage 1 hypertension, becomes cost-effective. A lifetime horizon Markov model c...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, 418.6KB)
-
- Publisher copy:
- 10.1161/hypertensionaha.120.14913
Authors
Bibliographic Details
- Publisher:
- Lippincott, Williams & Wilkins Publisher's website
- Journal:
- Hypertension Journal website
- Volume:
- 77
- Issue:
- 2
- Pages:
- 682-691
- Publication date:
- 2020-12-21
- Acceptance date:
- 2020-11-20
- DOI:
- EISSN:
-
1524-4563
- ISSN:
-
0194-911X
- Pmid:
-
33342242
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1152261
- Local pid:
- pubs:1152261
- Deposit date:
- 2021-02-05
Terms of use
- Copyright holder:
- Constanti et al.
- Copyright date:
- 2020
- Rights statement:
- ©2020 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record